Portal de Periódicos da CAPES

The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power

2018; Elsevier BV; Volume: 112; Linguagem: Inglês

10.1016/j.wneu.2018.01.045

1878-8769

Enrico Franceschi, Alicia Tosoni, Santino Minichillo, Roberta Depenni, Alexandro Paccapelo, Stefania Bartolini, Maria Michiara, Giacomo Pavesi, Benedetta Urbini, Girolamo Crisi, Michele Alessandro Cavallo, Luigino Tosatto, Claudio Dazzi, Claudia Biasini, Elena Pasini, Damiano Balestrini, Francesca Zanelli, Vania Ramponi, A. Fioravanti, Ermanno Giombelli, Dario de Biase, Agostino Baruzzi, Alba A. Brandes, Agostino Baruzzi, Fiorenzo Albani, Fabio Calbucci, Roberto D’Alessandro, Roberto Michelucci, Alba A. Brandes, Vincenzo Eusebi, Samuele Ceruti, Enrico Fainardi, R Tamarozzi, Ermanno Emiliani, Michele Alessandro Cavallo, Enrico Franceschi, A. Tosoni, Michele Alessandro Cavallo, Francesco Fiorica, A. Valentini, Roberta Depenni, Claudia Mucciarini, Girolamo Crisi, Enrico Sasso, Claudia Biasini, Luigi Cavanna, Donata Guidetti, Norina Marcello, Anna Pisanello, Anna Maria Cremonini, G. Guiducci, Silvia de Pasqua, S. Testoni, R. Agati, G. Ambrosetto, A. Bacci, Elisa Baldin, A. Baldrati, Elisa Barbieri, Stefania Bartolini, E. Bellavista, Francesca Bisulli, Elena Bonora, Feisal Bunkheila, Valério Carelli, Michela Crisci, P. Dall'Occa, Dario de Biase, Salvatore Ferro, Claudio Franceschi, G. Frezza, V. Grasso, Matilde Leonardi, Gianluca Marucci, Luca Morandi, Barbara Mostacci, Giorgio Palandri, Elisa Pasini, Marco Pastore Trossello, Annalisa Pession, Rosalba Poggi, P. Riguzzi, Roberta Rinaldi, Silvia Rizzi, G Romeo, F. Spagnolli, Paolo Tinuper, C. Trocino, Monia Dall’Agata, M. Frattarelli, G. Gentili, A. Giovannini, P. Iorio, U. Pasquini, Giuseppe Galletti, Carlo Guidi, Walter Neri, Alberto Patuelli, Silvia Strumia, Marina Faedi, Mario Casmiro, Alessandro Gamboni, F. Rasi, Giorgio Cruciani, P. Cenni, Claudio Dazzi, Alessandro Guidi, F. Zumaglini, Alberto Amadori, Elena Pasini, Mary Pasquinelli, E. Pasquini, A. Polselli, Alessandro Ravasio, Beatrice Viti, M. Sintini, Alessandra Ariatti, Federica Bertolini, Guido Bigliardi, P. Carpeggiani, Francesca Cavalleri, Stefano Meletti, Paolo Nichelli, Elisa Pettorelli, Guillaume Pinna, Elena Zunarelli, Fabrizio Artioli, Ilaria Bernardini, Matías Costa, Gabriele Greco, R. Guerzoni, C. Stucchi, Corrado Iaccarino, Moira Ragazzi, Romana Rizzi, Giulio Zuccoli, P. Api, F. Cartei, María Teresa Colella, Elisa Fallica, Marco Farneti, Antonio Frassoldati, Enrico Granieri, Francesco Latini, C Monetti, Andrea Saletti, R. Schivalocchi, S. Sarubbo, Silva Seraceni, Maria Rosaria Tola, Benedetta Urbini, G. Zini, Carlotta Giorgi, E. Montanari, Davide Cerasti, Pellegrino Crafa, Isabella Dascola, Irene Florindo, Ermanno Giombelli, S. Mazza, Vania Ramponi, Franco Servadei, Enrico Maria Silini, P Torelli, Paolo Immovilli, Nicola Morelli, C. Vanzo, C. Nobile,

Histone Deacetylase Inhibitors Research

Clinical and molecular factors are essential to define the prognosis in patients with glioblastoma (GBM). O6-methylguanine-DNA methyltransferase (MGMT) methylation status, age, Karnofsky Performance Status (KPS), and extent of surgical resection are the most relevant prognostic factors. Our investigation of the role of gender in predicting prognosis shows a slight survival advantage for female patients. We performed a prospective evaluation of the Project of Emilia Romagna on Neuro-Oncology (PERNO) registry to identify prognostic factors in patients with GBM who received standard treatment. A total of 169 patients (99 males [58.6%] and 70 females [41.4%]) were evaluated prospectively. MGMT methylation was evaluable in 140 patients. Among the male patients, 36 were MGMT methylated (25.7%) and 47 were unmethylated (33.6%); among the female patients, 32 were methylated (22.9%) and 25 were unmethylated (17.9%). Survival was longer in the methylated females compared with the methylated males (P = 0.028) but was not significantly different between the unmethylated females and the unmethylated males (P = 0.395). In multivariate analysis, gender and MGMT methylation status considered together (methylated females vs. methylated males; hazard ratio [HR], 0.459; 95% confidence interval [CI], 0.242–0.827; P = 0.017), age (HR, 1.025; 95% CI, 1.002–1.049; P = 0.032), and KPS (HR, 0.965; 95% CI, 0.948–0.982; P < 0.001) were significantly correlated with survival. Survival was consistently longer among MGMT methylated females compared with males. Gender can be considered as a further prognostic factor.